- SENIOR FACULTY Population Health Science and Policy
MA, University of Delhi
MS, University of Pittsburgh
PhD, Penn State University
Fellowship, Drexel University
- Madhu Mazumdar, PhD is Director of the Institute for Healthcare Delivery Science at the Mount Sinai Health System and is a Professor of Biostatistics at the Center of Biostatistics, Department of Population Health Science and Policy. She also directs the Biostatistics Core of Tisch Cancer Institute.
Dr. Mazumdar developed methodologies for detecting publication bias in meta-analysis; for adjusting selection bias in clinical trials; for allowing interim looks at data in clinical trials comparing diagnostic tests; for developing and validating quality of life questionnaire; and for estimating misclassification rate of responders when oncologic response criteria were changed. Her collaborative research resulted in personalized treatment regimen for various cancer types and orthopedic surgeries. Her work also changed guidelines for staging cancer and practice guidelines for use of anesthetics. She developed innovative interdisciplinary educational and research programs, in collaboration with various clinical departments that increased productivity through grantsmanship and augmented clinical revenue through improved care delivery. Working within inter-disciplinary teams, she has trained more than 50 biostatisticians, epidemiologists, and clinical researchers, many of whom are leading quantitative science units today.
2013 - 2013
American Statistical Association
2012 - 2012
Team Science Award
Sponsored jointly by American Federation of Medical Research, Association for Clinical Research Training, Association for Patient Oriented Research, Society for Clinical and Translational Science
2008 - 2008
American College of Epidemiology
Methodology Areas: Meta-analysis, Comparative Effectiveness Research, Clinical Trial Design, Prognostic and Predictive modeling,
Clinical Research Areas: Oncology, Anesthesiology, Radiology, Surgery
Biostatistics Module, MS in Healthcare Delivery Science and Leadership, ISMMS
Clinical Trials Design Workshop: Organized by the Radiological Society of North America, a Clinical Research Training Institute Summer Workshop: Organized by the American Society of Hematology
Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty: a study of efficacy and safety.; BMJ (In Press).
Poeran J, Mazumdar M, Memtsoudis SG. Anesthesia, Outcomes, and Public Health: Changing Health Care While “Asleep”. Reg Anesth Pain Med 2014; 39(3): 192-194.
Memtsoudis SG, Besculides MC, Mazumdar M. Rude Awakening — The Perioperative Sleep Apnea Epidemic. New England Journal of Medicine 2013; 368(25): 2352-3.
Memtsoudis SG, Chiu YL, Sun X, Ramachandran SK, Kaw R, Fleischu P, Mazumdar M. The impact of sleep apnea on postoperative utilization of resources and adverse outcomes. Anesth Analg 2014; 118: 407-418.
Memtsoudis SG, Danninge T, Rasul R, Poeran J, Gerner P, Stundner O, Mariano ER, Mazumdar M. Inpatient falls after total knee arthroplasty: the role of anesthesia type and peripheral nerve blocks. Anesthesiology 2014; 120(3): 551-63.
Memtsoudis SG, Sun X, Chiu YL, Stundner O, Liu SS, Banerjee S, Mazumdar M, Sharrock NE. Perioperative comparative effectiveness of anesthetic technique in orthopedic patients.. Anesthesiology 2013; 118: 1046-1058.
Pumberger M, Chiu YL, Ma Y, Girardi FP, Mazumdar M, Memtsoudis SG. National in-hospital morbidity and mortality trends after lumbar fusion surgery between 1998 and 2008. J Bone Joint Surg Br 2012; 94(3): 359-64.
Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18: 2972-2980.
Ma Y, Chu H, Mazumdar M. Meta-analysis of Proportions of Rare Events: A Comparison of Exact Likelihood Methods with Robust Variance Estimation. Communication in Statistics (In Press) 2014;.
Ma Y, Mazumdar M, Memtsoudis SG. Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Med 2012; 37(1): 99-105.
Ma Y, Mazumdar M. Multivariate meta-analysis: a robust approach based on the theory of the U-statistic. Stat Med 2011; 30(24): 2911-29.
Mazumda M, Zhou KX, Tu D. Some design issues underlying strata-matched non-randomized comparative studies with survival outcome. Stat. in Med 2006; 25: 3949-3959.
Mazumdar M, Smith A, Debroy PP, Schwartz LH. A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. J Clin Epidemiol 2005; 58(2): 150-3.
Mazumdar M. Group sequential design for comparative diagnostic accuracy studies: Implications and guidelines for practitioners. Medical Decision Making 2004; 24(5): 525-533.
Bacik J, Mazumdar M, Murphy BA, Fairclough DA, Eremenco S, Mariani T, Motzer RJ, Cella D. The Functional Assessment of Cancer Therapy-BRM (FACT-BRM): A New Tool for the Assessment of Quality of Life in Patients Treated with Biologic Response Modifiers. Quality Life Res 2004; 13(1): 37-54.
Mazumdar M, Liu A. Group Sequential Design for comparative diagnostic accuracy studies. Stat in Med 2003; 2: 727-739.
Mazumda M, Fazzari M, Panageas KS. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat in Med 2001; 20: 883-892.
Mazumdar M, Smith A, Tong WP, Motzer RJ. Calvert’s formula for dosing carboplatin: Overview and concerns of applicability in high-dose setting. J Natl Cancer Inst 2000; 92: 1434-1436.
Mazumdar M, Glassman JR. Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat in Med 2000; 19: 113-132.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Mazumdar did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
Icahn Medical Institute Floor 2nd Floor Room L2-70L
1425 Madison Avenue
New York, NY 10029